Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated With Post-Herpetic Neuralgia
4/23/2013 9:48:49 AM
More...
|
Convergence Pharmaceuticals Announces Successful Interim Data From Ground-Breaking Phase II Trigeminal Neuralgia Study
3/27/2013 9:26:32 AM
More...
|
Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
7/18/2012 10:08:05 AM
More...
|
Convergence Pharmaceuticals Announces Start of Phase II Study for CNV1014802 for Trigeminal Neuralgia
3/19/2012 9:06:50 AM
More...
|
Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
11/21/2011 7:17:17 AM
More...
|
Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
7/19/2011 6:25:45 AM
More...
|